Ipsen and Skyhawk Therapeutics announce a $1.8B collaboration to discover RNA-modulating small molecules for rare neurological diseases.

Ipsen and Skyhawk Therapeutics have announced a $1.8B collaboration to discover and develop novel RNA-modulating small molecules for rare neurological diseases. Ipsen holds an option to acquire global rights for candidates pursued under the partnership. Skyhawk's platform accelerates small molecule development, exploring previously undruggable RNA targets. The collaboration aims to develop transformative medicines for rare neurological diseases without approved treatments.